Brean Murray Initiates Coverage on Molecular Insight Pharmaceuticals (MIPI) with a Buy
More News related to MIPI
- Molecular Insight Announces Updates to Board of Directors
- Molecular Insight (MIPI) Announces New Strategic Plan to Align Operations
- Molecular Insight Pharmaceuticals Announces Personnel Reduction to Align Operations With Development Activities
- Unusual 11 Mid-Day Movers 12/30: PIP, ICXT, SEED, CYCC Higher; CBAK, TRMA, MIPI, MED Lower
- Jefferies & Co Downgrades Molecular Insight (MIPI) to Hold; Slashes PT
More News related to New Coverage
- Janney Montgomery Scott Initiates Coverage on Papa John's International (PZZA) with a Neutral
- Feltl & Co. Initiates Coverage on ActivIdentity (ACTI) with a Buy
- Oscar Gruss Initiates Coverage Airgas (ARG) with a Buy
- Sidoti & Co Initiates Coverage on Solutia (SOA) with a Buy
- RBC Capital Initiates Coverage on Questar (STR) with a Sector Perform
Brean Murray initiates coverage on Molecular Insight Pharmaceuticals (Nasdaq: MIPI) with a Buy. Price target $11.
To see more analyst ratings on MIPI Click Here.
Molecular Insight Pharmaceuticals, Inc., a development stage biopharmaceutical company, engages in the research, development, and commercialization of molecular imaging pharmaceuticals and radiotherapeutics primarily in the areas of oncology and cardiology in the United States.
Related Categories
New CoverageStocks Mentioned
+0.04Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
